In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a price target of $41.00. The company’s shares closed yesterday at $15.30.
According to TipRanks, Farmer is a 5-star analyst with an average return of 22.6% and a 61.11% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Syndax Pharmaceuticals, and Tempest Therapeutics.
In addition to Scotiabank, Biomea Fusion also received a Buy from Barclays’s Peter Lawson in a report issued today. However, on the same day, J.P. Morgan downgraded Biomea Fusion (NASDAQ: BMEA) to a Hold.
The company has a one-year high of $43.69 and a one-year low of $8.13. Currently, Biomea Fusion has an average volume of 978K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biomea Fusion (BMEA) Company Description:
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Read More on BMEA:
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Largest borrow rate increases among liquid names
- Biomea Fusion options imply 6.2% move in share price post-earnings
